Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Travel Med Infect Dis ; 10(1): 48-51, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22212199

RESUMEN

This report reviews U.S. guidelines for the identification of persons exposed to rubella during air travel. In response to an individual with rubella who traveled on multiple flights, CDC conducted an airline contact investigation that was expanded beyond customary protocol to assess if current operating procedures are adequate. Of 250 potentially exposed airline passengers, 215 (86%) were contacted and none developed a rubella-like rash, arguing against the need to notify passengers beyond the standard protocol in most cases.


Asunto(s)
Aviación , Trazado de Contacto , Rubéola (Sarampión Alemán)/prevención & control , Rubéola (Sarampión Alemán)/transmisión , Viaje , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antivirales/sangre , Centers for Disease Control and Prevention, U.S. , Niño , Preescolar , Femenino , Guías como Asunto , Humanos , India , Lactante , Masculino , Persona de Mediana Edad , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/epidemiología , Vacuna contra la Rubéola/uso terapéutico , Virus de la Rubéola/inmunología , Virus de la Rubéola/aislamiento & purificación , Estados Unidos/epidemiología , Adulto Joven
2.
Public Health Rep ; 126 Suppl 2: 78-86, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21812172

RESUMEN

OBJECTIVES: We described the uptake and coverage rates of meningococcal conjugate vaccine (MCV4); tetanus-diphtheria-acellular pertussis vaccine (Tdap); and quadrivalent human papillomavirus vaccine (HPV4) in North Dakota using the North Dakota Immunization Information System (NDIIS). METHODS: We analyzed all available MCV4, Tdap, and HPV4 doses given after vaccine licensure and through December 31, 2009, obtained from the NDIIS to identify trends and patterns in vaccine administration. We analyzed all data by administration date, age group, and health-care provider type. We also calculated missed opportunities to complete all recommended vaccines among vaccinated adolescents. RESULTS: For adolescents aged 13-17 years, 69.2% had > or = 1 dose of Tdap and 62.8% had > or = 1 dose of MCV4. Of females aged 13-17 years, 42.8% initiated the HPV4 vaccination series and 24.9% received > or = 3 HPV4 doses. Only 48.7% of males aged 13-17 years received both Tdap and MCV4 at the same visit, and only 11.5% of females aged 13-17 years received Tdap, MCV4, and HPV4 doses at the first visit. CONCLUSIONS: The NDIIS is useful in tracking adolescent vaccine uptake. The immunization rates for all three routinely recommended adolescent vaccines are rising in North Dakota, although at different paces. Providers should be educated about the importance of not missing opportunities to vaccinate, and school-based vaccination clinics should be used to reach adolescents who are less likely to have preventive care visits.


Asunto(s)
Sistema de Registros/estadística & datos numéricos , Vacunas , Adolescente , Factores de Edad , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular , Femenino , Encuestas Epidemiológicas/estadística & datos numéricos , Humanos , Masculino , Vacunas Meningococicas , North Dakota/epidemiología , Vacunas contra Papillomavirus
3.
N Engl J Med ; 360(9): 886-92, 2009 Feb 26.
Artículo en Inglés | MEDLINE | ID: mdl-19246360

RESUMEN

We report on three cases of meningococcal disease caused by ciprofloxacin-resistant Neisseria meningitidis, one in North Dakota and two in Minnesota. The cases were caused by the same serogroup B strain. To assess local carriage of resistant N. meningitidis, we conducted a pharyngeal-carriage survey and isolated the resistant strain from one asymptomatic carrier. Sequencing of the gene encoding subunit A of DNA gyrase (gyrA) revealed a mutation associated with fluoroquinolone resistance and suggests that the resistance was acquired by means of horizontal gene transfer with the commensal N. lactamica. In susceptibility testing of invasive N. meningitidis isolates from the Active Bacterial Core surveillance system between January 2007 and January 2008, an additional ciprofloxacin-resistant isolate was found, in this case from California. Ciprofloxacin-resistant N. meningitidis has emerged in North America.


Asunto(s)
Antiinfecciosos/uso terapéutico , Ciprofloxacina/uso terapéutico , Farmacorresistencia Bacteriana/genética , Infecciones Meningocócicas/tratamiento farmacológico , Neisseria meningitidis/genética , Mutación Puntual , Adolescente , Adulto , Anciano , Secuencia de Bases , Portador Sano/microbiología , Humanos , Lactante , Infecciones Meningocócicas/microbiología , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Neisseria meningitidis/clasificación , Neisseria meningitidis/efectos de los fármacos , Neisseria meningitidis/aislamiento & purificación , Faringe/microbiología , Estados Unidos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...